Article
Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.
Journal of medicinal chemistry - 24 Dec 2015
Pesci Elisabetta, Bettinetti Laura, Fanti Paola, Galietta Luis J V, La Rosa Salvatore, Magnoni Letizia, Pedemonte Nicoletta, Sardone Gian Luca, Maccari Laura
Abstract excerpt
Cystic fibrosis (CF) is a lethal genetic disease caused by mutations of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) with a prevalence of the ΔF508 mutation. Whereas the detailed mechanisms underlying disease have yet to be fully elucidated, recent breakthroughs in clinical trials have demonstrated that CFTR dysfunction can be corrected by drug-like molecules. On the basis of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
